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Abstract
Background: Recent evidence has proven that long noncoding RNAs (lncRNAs) play important roles in cancer
biology, while few lncRNAs have been characterized in NSCLC. Here, we characterized a novel lncRNA, SBF2
antisense RNA 1 (SBF2-AS1), in non-small cell lung cancer (NSCLC).
Methods: Quantitative real-time PCR was used to quantify SBF2-AS1 expression in NSCLC tissues and cell lines. The
correlation of SBF2-AS1 expression with clinicopathologic features was analyzed in a cohort NSCLC patient. Loss of
function and gain of function studies were performed to determine the effects of SBF2-AS1 on proliferation and
metastasis of NSCLC cells. RNA immunoprecipitation and chromosome immunoprecipitation assay was performed
to confirm the interaction between SBF2-AS1 with protein and chromosome.
Results: We confirmed that SBF2-AS1 was significantly upregulated in NSCLC compared with corresponding
non-tumor tissues, and a high expression level of SBF2-AS1 was correlated with lymph node metastasis and
advanced TNM stage. Using siRNAs specifically targeting SBF2-AS1 and plasmid vector, we successfully
silenced and overexpressed SBF2-AS1 in NSCCLC cell lines and investigated its biological function both in
vitro and in vivo. After the silencing of SBF2-AS1, the metastasis of NSCLC cells was significantly inhibited,
the silencing of SBF2-AS1 decreased the proliferation of NSCLC cells, and the cell cycle was arrested at the
G1 phase; while overexpression promoted proliferation ability. Xenograft tumor models revealed that the
silencing of SBF2-AS1 inhibited tumor growth in vivo. We speculated that SBF2-AS1 might negatively regulate
P21. RNA immunoprecipitation discovered that SBF2-AS2 could bind with a core component of polycomb
repressive complex2, SUZ12. Additionally chromatin immunoprecipitation assay demonstrated that, after
silencing SBF2-AS1, the enrichment of SUZ12 and trimethylation of histone 3 lysine 27 decreased at the
promoter region of P21.
Conclusions: We demonstrated that SBF2-AS1 is upregulated in NSCLC and promotes proliferation of NSCLC
tumor cells. SBF2-AS1 may serve as a novel biomarker and potential therapeutic target for NSCLC patients.
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Background
In the past decades, lung cancer has been the leading
cause of cancer-related death worldwide [1]. Non-small
cell lung cancer (NSCLC) is the most common type of
lung cancer, which consists of two most common
histological types, squamous cell carcinoma and adeno-
carcinoma. To date, the improvements in the treat-
ment of lung cancer have been achieved by the
development of combined treatments, such as surgical
resection, systemic chemotherapy and targeted drugs.
However, the overall five-year survival rate of NSCLC
remains unsatisfactory [2]. Therefore, to develop more
effective treatment methods, it is urgent to fully dis-
cover the genetic and molecular features of NSCLC.
Recently, evidence has shown that at least 90 % of the
total mammalian genome is actively transcribed [3].
However, only approximately 1.5 % of the genome se-
quence comprise protein-coding genes [4]. Non-protein-
coding RNA (ncRNA) transcripts consist of >98 % of the
mammalian transcriptome and were once thought to be
“junk” or “transcription noise”. Recent evidence has
proven that ncRNAs—for example microRNAs—play
significant roles in various biological processes [4–6].
Long noncoding RNAs (lncRNAs), ncRNAs larger than
200 nucleotides, play a crucial role in diverse cellular
processes such as cell growth [7], differentiation [8], the
immune response [9], and cancer metastasis [10–12].
By analyzing a published lncRNA microarray dataset of
NSCLC [13], we found that the novel lncRNA SBF2 anti-
sense RNA 1 (SBF2-AS1) was significantly upregulated in
NSCLC tissues compared with the corresponding non-
tumor tissues. SBF2-AS1 is a 2708 nt antisense RNA to
SBF2, which is located at the 11p15.1 locus. However, the
expression profile and potential function of SBF2-AS1 in
NSCLC remain unknown. In the present study, we vali-
dated the upregulation of SBF2-AS1 in NSCLC and found
that a high expression level of SBF2-AS1 was correlated
with advanced TNM stage. Using small interfering RNA
(siRNA)-mediated silencing of SBF2-AS1, NSCLC cell
proliferation was inhibited both in vivo and in vitro.
Methods
Patients and tissue samples
Primary NSCLC tissues and adjoining normal tissues were
collected from patients received surgical resection of
NSCLC from 2012 to 2014 at the Department of Thoracic
Surgery, Cancer Institute of Jiangsu Province. All patients
did not receive radiotherapy or chemotherapy before
surgical resection. All tumor specimens and adjoining
normal specimens were snap-frozen immediately after
resection, and stored in liquid nitrogen until total RNA
extraction. All tumor and paired normal tissues were veri-
fied by experienced pathologists. Clinical characteristics
were also collected for each patient, and informed written
consents were obtained from all patients included in this
research. This study was approved by the Ethics Boards of
the Cancer Institute of Jiangsu Province.
Cell lines and culture conditions
All cell lines (A549, NCI-H1975, NCI-H358, NCI-H1299,
SPC-A1, and human bronchial epithelial cell (HBE)) were
purchased from Shanghai Institutes for Biological Science,
China. NCI-H1975, A549 and NCI-H1299 cells were
cultured in RPMI 1640 medium (KeyGene, Nanjing,
China), NCI-H358, SPC-A1, and HBE cells were cultured
in DMEM medium (KeyGene, Nanjing, China), supple-
mented with 10 % fetal bovine serum with 100U/ml peni-
cillin and 100 mg/ml streptomycin included. All cell lines
were grown in humidified air at 37 °C with 5 % CO2.
RNA extraction and qRT-PCR analyses
Total RNA was isolated with TRIzol reagent (Life Tech-
nologies, Scotland, UK) according to the manufacturer’s
protocol. About 1.0ug total RNA was reverse transcribed
in a final volume of 20ul using the PrimeScript RT
Master Mix (Takara, Cat.#RR036a) according to the
manufacturer’s protocol. After reverse transcription, the
quantitative real-time polymerase chain reaction (qRT-
PCR) was carried out using the SYBR Select Master Mix
(Applied Biosystems, cat: 4472908) with 0.5ul cDNA on
ABI 7900 system (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions. The
relative levels of SBF2-AS1 were confirmed by qRT-PCR.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and β-actin were measured as internal controls. The
qRT-PCR reaction was implemented under the following
conditions: 95 °C for 10 min, 40 cycles of 95 °C for 15 s,
and 60 °C for 1 min. The fold changes of individual
genes were calculated by 2-ΔΔCt methods [14]. QRT-
PCR primers used were: 5′-GGACTAGTGGAGAAGG
TGCG-3′ (Forward) and 5′-GGGCGCTGCCCATCA
TCATG-3′ (Reverse) for P15, 5′-AAACTTGGAAA
TCCCGAGATTGC-3′ (Forward) and 5′-CGAAACC




3′ (Forward) and 5′-CAAGCAGTGATGTATCTGAT
AAACAAGG-3′ (Reverse) for P27, 5′-CACCGAATA
GTTACGGTCGG-3′ (Forward) and 5′-GCACGGGTC
GGGTGAGAGTG-3′ (Reverse) for P16, 5′-AGGCT
GACCACGAGCTTTTC-3′ (Forward) and 5′-GGTG
CTATGAGATTCCGAGTTC-3′ (Reverse) for SUZ12,
5′-GAAATCGTGCGTGACATTAA-3′ (Forward) and
5′-AAGGAAGGCTGGAAGAGTG-3′ (Reverse) for β-
actin, and 5′-CCACATCGCTCAGACACCAT -3′ (For-
ward) and 5′-ACCAGGCGCCCAATACG -3′ (Reverse)
for GAPDH.
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Western blot assay
Cells were harvested, and protein was extracted from
transfected cells and quantified as previously described49
using 12 % or 4 ~ 20 % polyacrylamide gradient SDS gel.
Anti-β-actin and anti-SUZ12 were from Abcam (Hong
Kong, China). Anti-P21 and anti-Cyclin D1 were from
Cell Signaling Technology (Boston, MA, USA).
siRNA and plasmid transfection of NSCLC cells
A549 and H1975 cells were planted in six-well plate
24 h before transfection. When they were about 70 %
confluent, cells were transfected with siRNA targeting
specific genes or negative control (RealGene, Nanjing,
China) by using the Lipofectamine RNAimax reagent
(Invitrogen, USA) according to the protocol provided by
the manufacturer. The siRNA sequences for SBF2-AS1
were 5′-CAGAAGGAGUCUACUGCUAAG-3′ (Sense)
and 5′-UAGCAGUAGACUCCUUCUGGG-3′ (Anti-
sense) for 204 site and 5′-GCAAGCCUGCAUGGUA
CAUTT -3′ (Sense) and 5′-AUGUACCAUGCAGG
CUUGCTT -3′ (Antisense) for 1021 site. The siRNA
sequences for SUZ12 were 5′-GUCGCAACGGACCA
GUUAATT-3′ (Sense) and 5′-UUAACUGGUCCGUU
GCGACTT-3′ (Antisense).
The SBF2-AS1 sequence was synthesized according to
the full-length SBF2-AS1 sequence (based on the GAS5
sequence, NR_002578, in NCBI) and then subcloned
into a pCDNA3.1 vector (Invitrogen, Shanghai, China).
The pCDNA-GAS5 or empty vector was transfected into
SPC-A1 cells using Lipofectamine 3000 reagent (Invitro-
gen, USA), according to the manufacturer’s instructions.
The empty pcDNA3.1 vector was used as the control.
Cell proliferation assay
Cell proliferation was assayed by Cell Counting Kit-8
(CCK8) assay (Promega). The transfected cells were
plated in 96-well plates (4000cells per well) 24 h after
transfection and cultured at 37 °C and 5 % CO2 atmos-
phere. CCK8 assay was used to detect the relative cell
growth every 24 h according to the instructions of
manufacturer. Simply, 20ul of CCK8 solution was added
to each well, and each well was measured spectrophoto-
metrically at 450 nm after incubating for 2 h.
Cell migration and invasion assays
For migration assay, transfected cells (3 * 105) were plated
in the upper chamber of transwell assay inserts (8 mm
pores, Millipore, Billerica, MA) containing 200ul of
serum-free 1640 medium. The lower chambers were filled
with 1640 containing 10 % FBS. After 24 h of incubation,
the cells on the filter surface were fixed with methanol,
stained with crystal violet, and photographed. Migration
was assessed by counting the number of stained cell nuclei
from 5 random fields per filter in each group.
For invasion assay, transfected cells (5 * 105) were plated
in the top chamber with a matrigel-coated membrane (BD
Biosciences) in 500ul serum-free 1640. Also, the bottom
chambers were filled with conditioned 1640. The invasion
function was determined after incubating 48 h as men-
tioned previously in migration.
Flow-cytometric analysis
Transfected cells were harvested after transfection by
trypsinization. After the double staining with fluorescein
isothiocyanate (FITC)-Annexin V and propidium iodide
was done by the FITC Annexin V Apoptosis Detection
Kit (BD Biosciences) according to the manufacturer’s
recommendations. The cells were analyzed with a flow
cytometry (FACScan; BD Biosciences) equipped with a
Cell Quest software (BD Biosciences). Cells for cell-cycle
analysis were stained with propidium oxide by the Cycle
TEST PLUS DNA Reagent Kit (BD Biosciences) follow-
ing the protocol and analyzed by FACScan. The percent-
age of the cells in G1, S, and G2–M phase were counted
and compared.
RNA immunoprecipitation (RIP)
RIP experiments were performed using a Magna RIP
RNA-Binding Protein Immunoprecipitation Kit (Millipore)
according to the manufacturer’s instructions. Antibodies
of EZH2 and SUZ12 were from Abcam.
Chromatin immunoprecipitation (ChIP) assays
The ChIP assays were performed using EZ-CHIP KIT
according to the manufacturer’s instruction (Millipore,
Billerica, MA, USA). H3K27 antibody was from Millipore.




Transient transfection was performed in A549 cells with
shLUADT1 or scrambled control sequence using Lipofec-
tamine 2000 (Invitrogen). After 48 h of transfection, the
cells were collected and injected into either side of the
posterior flank of the same male BALB/c nude mouse.
The tumor volumes and weights were measured every
2 days in the mice; the tumor volumes were measured as
length × width2 × 0.5. Sixteen days after injection, the mice
were sacrificed, the tumor weights were measured, and
the tumors were collected for further analysis. The
LUADT1 levels were determined by qRT-PCR.
Immunohistochemistry
Xenograft tumor tissue samples were immunostained
for p27 and Ki67. Anti-Ki67 was from Santa Cruz
Biotechnology.
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Statistical analysis
Student’s t-test, one-way ANOVA analysis, and Spearman
test were performed to analyze the data using SPSS 18.0
software. P < 0.05 was considered statistically significant.
Results
Upregulation of SBF2-AS1 in NSCLC
Inspired by a previous study that analyzed the lncRNA
expression profile of NSCLC in Chinese patients [13],
we found that the novel lncRNA SBF2-AS1 was upreg-
ulated in lung adenocarcinoma (Fig. 1a). In an expres-
sion cohort of 41 lung cancer patients, we confirmed
that SBF2-AS1 was significantly upregulated in lung
cancer patients compared with paired adjacent non-
tumor tissues (P < 0.01). As shown in Fig. 1b, upregula-
tion of SBF2-AS1 was observed in 36 of 41 patients
with an average fold increase of 5.36. In addition to our
expression cohort, we also validated the overexpression
of SBF2-AS1 in another set of microarrays of lung
cancer patients from the Gene Expression Omnibus
(GSE19804) [15]. As shown in Fig. 1c, the expression of
SBF2-AS1 was quite homogeneous, and overexpression
was found in 53 of 60 cases.
We further analyzed the relationships between the
SBF2-AS1 expression levels and clinicopathological fea-
tures of NSCLC patients. As shown in Table 1, there
was no significant difference between gender, age, or
smoking status and the expression level of SBF2-AS1.
Fig 1 SBF2-AS1 is overexpressed in NSCLC tissues. Expression heatmap of differentially expressed genes in NSCLC (a) and SBF2-AS1 was highlighted.
Expression level of SBF2-AS1 in a cohort of NSCLC patients (b) and the GSE19804 dataset (c). Red: upregulation, green: downregulation. Differential
expression level of SBF2-AS1 between the different lymph nodes (d) and TNM (e) stages. * P < 0.05
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However, the expression level of SBF2-AS1 was signifi-
cantly correlated with lymph node stage (P = 0.032,
Fig. 1d) and TNM stage (P = 0.047, Fig. 1e), and a
higher expressed level indicated advanced stage. Thus,
these lines of evidence demonstrated that SBF2-AS1
was upregulated in NSCLC and correlated with ad-
vanced TNM stage.
Silencing of SBF2-AS1 inhibited the proliferation and
metastasis of NSCLC cells
We compared the expression of SBF2-AS1 between
NSCLC cell lines and human bronchial epithelial
(HBE) cells, and the results revealed that SBF2-AS1
was upregulated in most NSCLC cell lines and
showed the highest expression level in A549 and
H1975 cells, while the expression in SPC-A1 cell line
was lower (Fig. 2a). Thus, A549,H1975, and SPC-A1
were utilized as cell models to investigate the bio-
logical function of SBF2-AS1. Two small interfering
RNA sequences were designed to specifically target
SBF2-AS1 at the 204 (siRNA1) and 1021 (siRNA2)
sites. As shown, siRNA2 showed better inhibition
Fig 2 SBF2-AS1 is overexpressed in most NSCLC cell lines compared with the normal human bronchus epithelium cell line HBE (a). SBF2-AS1
was efficiently inhibited by siRNA in the A549 (b) and H1975 (c) cell lines compared with NC and pcDNA3.1-SBF2-AS1 successfully overexpressed
SBF2-AS1 in SPC-A1 cells (d) compared with empty vector (EV). After the silencing of SBF2-AS1, proliferation and colony formation ability were
significantly inhibited in the A549 (e, h) and H1975 (f, i) cell lines, while overexpression of SBF2-AS1 increased proliferation ability and colony
formation ability in SPC-A1 cells (g, j). * P < 0.05, **P < 0.01
Table 1 Relationship between SBF2-AS1 expression and
clinicopathological characteristics
Groups Upregulation Fold Number of Patients P Value
Gender Male 7.57 19 0.442
Female 3.46 22
Age ≤65 5.90 32 0.55
>65 3.45 9
Smoke No 5.96 34 0.62
Yes 2.45 7
N Stage 0 3.06 30 0.032a
1 1.96 6
2 23.27 5
T Stage 1 3.60 28 0.436
2 9.89 12
3 0.41 1
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efficacy, and siRNA2 was used in subsequent experi-
ments (Fig. 2b, c). Additionally, expression of SBF2-
AS1 was significantly over-expressed in SPC-A1 cells
by plasmid (Fig. 2d).
Cell proliferation ability was first analyzed. The CCK8
assay showed that, after silencing of SBF2-AS1, the prolif-
eration ability of A549 and H1975 cells was significantly
decreased, and the inhibition was more remarkable in
A549 cells, while overexpression of SBF2-AS1 increased
proliferation ability of SPC-A1 cells (Fig. 2e, f, g). Next,
colony formation assay was conducted. Compared with
the negative control, siRNA treatment significantly inhib-
ited the colony formation ability of NSCLC cell lines
(Fig. 2h, i). In contrast, overexpression of SBF2-AS1
increased the number of colonies in SPC-A1 cells
compared with empty vector. After treatment with NC
and siRNA, the cells were stained with propidium
iodide and analyzed by flow cytometry. We observed
significant cell cycle arrest at the G1 phase with a
remarkable decrease in S phase (Fig. 3a, b). To support
the flow cytometry results (Fig. 3c), Western blotting
was performed and revealed that Cyclin D1 was also
decreased after the silencing of SBF2-AS1. Addition-
ally, apoptosis was investigated by flow cytometry; no
statistically significant difference was found (Fig. 4).
Therefore, these results showed that the silencing of
SBF2-AS1 inhibited the proliferation ability of NSCLC
cells through cell cycle arrest.
We further analyzed the effect of SBF2-AS1 on cell
metastasis. Transwell and matrigel assays showed that
the silencing of SBF2-AS1 significantly decreased the
metastasis ability of A549 and H1975 cell lines (Fig. 5).
Silencing of SBF2-AS2 inhibited tumor growth in vivo
To probe whether SBF2-AS1 regulates NSCLC cell
proliferation in vivo, we established xenograft tumor
models in nude mice using A549 cells transfected with
negative control or siRNA targeting SBF2-AS1. As
Fig 3 Cell cycle analysis was performed after the silencing of SBF2-AS1 in the A549 (a) and H1975 (b) cell lines. Significant G1 phase arrest and S
phase decrease were observed in both cell lines. Western blotting showed that the Cyclin D1 protein level was decreased after the silencing of
SBF2-AS1 in A549 cells (c) and H1975 cells (d)
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shown in Fig. 6, SBF2-AS1 silencing inhibited tumor
growth in vivo. Xenograft tumors derived from A549
cells transfected with siRNA targeting SBF2-AS1
showed a smaller volume and lower weight than those
derived from cells transfected with NC (Fig. 6c, d). In
consistence with in vitro results, silence of SBF2-AS1
inhibited proliferation of NSCLC cells, as the prolifera-
tion marker Ki-67 was weaker in the siRNA group than
the NC group (Fig. 6e).
SBF2-AS2 inhibited P21 by binding to SUZ12
Because remarkable G1 cell cycle arrest was observed
after the silencing of SBF2-AS1, we analyzed the expres-
sion of cyclin-dependent kinase inhibitor (CKI) family
genes, key regulators of cell cycle, by qRT-PCR. As
shown, we found that P21 was significantly upregulated
after the silencing of SBF2-AS1, a finding that was also
confirmed at the protein level (Fig. 7a). Thus, it is highly
possible that SBF2-AS1 controls the cell cycle by regu-
lating P21.
Currently, most reported lncRNAs have been shown
to play roles in transcription regulation, primarily epi-
genetic modification. Khalil et al. [16] reported that
20 % lncRNA could bind to polycomb repressive com-
plex 2 (PRC2). PRC2 is a critical regulator of histone
modification, which negatively regulates gene expression
by catalyzing the trimethylation of H3K27. Evidence has
proved that that PRC2 is an important driver of tumor
development and progression by suppressing various
key genes. Thus, we hypothesized that SBF2-AS1 might
modulate P21 expression by binding to PRC2. Using an
RNA immunoprecipitation (RIP) assay, we confirmed
that SBF2-AS1 could bind to SUZ12 and EZH2, the
core components of PRC2 (Fig. 7b, c). Compared with
the negative control IgG, SBF2-AS1 was significantly
enriched by SUZ12 and EZH2 antibodies, and the effect
was more evident for SUZ12. In addition to the RIP
assay, we performed a chromatin immunoprecipitation
(ChIP) assay to investigate whether the silencing of
SBF2-AS1 affects the enrichment of PRC2 and tri-
methylation of histone 3 lysine 27 (H3K27 me3) at the
Fig. 4 Apoptosis is not affected by the silencing of SBF2-AS1 in the A549 (a) or H1975 (b) cell lines
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promoter region of P21. As revealed by ChIP assay,
after the silencing of SBF2-AS1, the enrichment of
SUZ12 and EZH2 was significantly decreased, as well as
that of H3K27 me3, at the promoter region of P21
(Fig. 7d). To confirm this finding, we silenced SUZ12 by
siRNA, and increased RNA and protein expression of
P21 were also observed (Fig. 7e, f ). To validate the
reverse relationship between SBF2-AS1 and P21, we
retrieved the expression values of SBF2-AS1 and P21
from the GSE19804 dataset and found that the expres-
sion of the two genes were significantly negatively cor-
related (P = 0.009, Fig. 8a). In addition, in xenograft
tumor models immunohistochemistry assay showed that
P21 staining was also stronger in the siRNA group
(Fig. 8b). Thus, we confirmed that SBF2-AS1 regulated
the transcription of P21 by binding to PRC2.
Fig. 5 Transwell and migration assays showed that metastasis was inhibited by the silencing of SBF2-AS1 in the A549 (a, c) and H1975 (b, d) cell lines
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Fig. 6 Xenograft tumor models were developed in nude mice by A549 cells transfected with NC and siRNA targeting SBF2-AS1. The xenograft
tumor volume (a, b, c) and weight (d) in the SBF2-AS1 siRNA group were significantly lower than those in the NC group. Immunohistochemistry
assay showed that Ki-67 staining was weaker in the siRNA group (e)
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Discussion
In the current study, we characterized the expression
profile of SBF2-AS1 in NSCLC and found that high ex-
pression of SBF2-AS1 was associated with advanced
TNM stage. By the silencing of SBF2-AS1, the cell pro-
liferation and metastasis ability was inhibited in vitro.
The silencing of SBF2-AS1 also inhibited xenograft
tumor growth in vivo. Thus, SBF2-AS1 could potentially
function as an oncogenic gene in NSCLC.
The mortality rate of lung cancer is higher in males
than in females [17]. However, the precise molecular
mechanism involved in lung carcinogenesis remains elu-
sive. It has been widely accepted that many lncRNAs
transcribed from the human genome have play broad
roles in lung cancer [18]. Numerous studies have sug-
gested that lncRNAs are involved in various malignant
tumors, such as those of the brain [19, 20], lung [11, 21],
breast [22], pancreas [23, 24] and liver [25]. This extends
our knowledge concerning carcinogenesis and provides a
new pathway in cancer research. For lung cancer, various
lung cancer-specific lncRNAs have been identified, such
as MALAT1 [26, 27], TARID [28], and LUADT1 [29].
Fig. 7 After the silencing of SBF2-AS1, P21 was significantly upregulated as detected by RT-PCR and Western blotting (a). The RIP assay demonstrated
that SBF2-AS1 could significantly bind to SUZ12 and EZH2 compared with the negative control IgG in A549 (b) and H1975 (c) cells. ChIP assay showed
that the enrichment of SUZ12, EZH2, and H3K27me3 was decreased at the promoter region of P21 by the silencing of SBF2-AS1 in A549 cells (d). By
silencing SUZ12 in A549 cells, the RNA (e) and protein (f) levels of P21 were significantly upregulated
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SBF2-AS1 is a novel lncRNA transcribed from
chromosome 11p15.4, a finding that has not been
reported previously. Firstly, we explored the expression
of SBF2-AS1 in NSCLC tissues and analyzed the rela-
tionship between the SBF2-AS1 expression level and
clinical characteristics, such as gender, tumor size, and
TNM stage. As indicated by the microarray data, SBF2-
AS1 was upregulated in NSCLC tissues compared with
adjacent non-tumor tissues, and the expression was very
homogeneous. Similarly, SBF2-AS1 was overexpressed in
the 4 NSCLC cell lines analyzed. Statistical analyses
revealed that the overexpression of SBF2-AS1 was asso-
ciated with lymph node metastasis and advanced TNM
stage, indicating that SBF2-AS1 could be a biomarker
for NSCLC and might be a prognostic factor for survival.
The predictive value of SBF2-AS1 should be validated by
more experimental evidence.
After siRNA-mediated silencing of SBF2-AS1, we
found that SBF2-AS1 could modulate cell proliferation
and overexpression of SBF2-AS1 increased proliferation
ability of NSCLC cells. In recent years, some lncRNAs,
including growth-arrest-specific transcript 5 [30] (GAS5),
prostate-specific gene 1 (PCGEM1) [31], prostate-cancer-
associated transcript 1 (PCAT-1) [32], and colon cancer-
associated transcript 2 (CCAT2) [33], have been reported
to regulate tumor cell growth and progression by altering
the balance between cell proliferation and apoptosis. In
the present study, we also found that SBF2-AS1 influ-
enced tumor cell proliferation by affecting cell cycle dis-
tribution. The flow cytometric analysis suggested that the
cell cycle was arrested at the G1 phase after transfection
with siRNA. According to Khalil et al., most lncRNAs
could bind to the PRC2 complex and negatively regulate
gene expression at the transcription level [16], such as
the lncRNAs HOTAIR [34, 35] and TUG1 [36]. We
found that SBF2-AS1 could also bind to the PRC2 com-
plex, particularly the subunit SUZ12. ChIP assay revealed
that the silencing of SBF2-AS1 decreased the enrichment
of SUZ12 and H3K27 me3 at the promoter region of
P21. Thus, these experiments demonstrated that SBF2-
AS1 could modulate the cell cycle through epigenetic
inhibition of P21.
Metastasis is another important malignant behavior of
cancer and is the most troublesome problem in tumor
Fig. 8 The negative correlation between SBF2-AS1 and P21 was confirmed in the GSE19804 dataset (a). In the xenograft tumor tissues derived
from siRNA group, P21 staining was stronger than the NC group (b)
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prognosis and therapy. lncRNAs involved in the regula-
tion of tumor metastasis have also been reported, and
include MALAT-1 [26] and HOX antisense intergenic
RNA (HOTAIR) [35]. Our study suggested that the
migration and invasion ability of NSCLC cells were
significantly decreased by the silencing of SBF2-AS1,
suggesting SBF2-AS1 is also an important regulator of
metastasis.
Conclusion
In this study, we identified a novel lncRNA SBF2-AS1 in
NSCLC that is upregulated and correlated with ad-
vanced TNM stage. SBF2-AS1 could promote prolifera-
tion of NSCLC cells in vitro and in vivo, suggesting that
SBF2-AS1 might be an oncogenic lncRNA in NSCLC.
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